Celecoxib, a selective inhibitor of COX-2, has demonstrated its chemotherapeutic properties in a variety of cancers including colon, breast, skin, prostate, and pancreatic cancer cells, but was never tested in KSHV-associated malignancies (Jendrossek, 2013). Here, PTGS2 is linked to pancreatic neoplasm.